These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24389382)

  • 1. Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells.
    Pei Q; Pan J; Zhu H; Ding X; Liu W; Lv Y; Zou X; Luo H
    Int Immunopharmacol; 2014 Mar; 19(1):10-6. PubMed ID: 24389382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine sensitizes pancreatic cancer cells to the CTLs antitumor response induced by BCG-stimulated dendritic cells via a Fas-dependent pathway.
    Pei Q; Pan J; Ding X; Wang J; Zou X; Lv Y
    Pancreatology; 2015; 15(3):233-9. PubMed ID: 25937078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
    Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
    J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells.
    Dauer M; Herten J; Bauer C; Renner F; Schad K; Schnurr M; Endres S; Eigler A
    J Immunother; 2005; 28(4):332-42. PubMed ID: 16000951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer.
    Shindo Y; Hazama S; Maeda Y; Matsui H; Iida M; Suzuki N; Yoshimura K; Ueno T; Yoshino S; Sakai K; Suehiro Y; Yamasaki T; Hinoda Y; Oka M
    J Transl Med; 2014 Jun; 12():175. PubMed ID: 24947606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.
    Bauer C; Sterzik A; Bauernfeind F; Duewell P; Conrad C; Kiefl R; Endres S; Eigler A; Schnurr M; Dauer M
    Cancer Immunol Immunother; 2014 Apr; 63(4):321-33. PubMed ID: 24384835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells.
    Smith PL; Yogaratnam Y; Samad M; Kasow S; Dalgleish AG
    Clin Transl Oncol; 2021 Jan; 23(1):110-121. PubMed ID: 32661823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer.
    Hirooka Y; Itoh A; Kawashima H; Hara K; Nonogaki K; Kasugai T; Ohno E; Ishikawa T; Matsubara H; Ishigami M; Katano Y; Ohmiya N; Niwa Y; Yamamoto K; Kaneko T; Nieda M; Yokokawa K; Goto H
    Pancreas; 2009 Apr; 38(3):e69-74. PubMed ID: 19276867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.
    Bauer C; Bauernfeind F; Sterzik A; Orban M; Schnurr M; Lehr HA; Endres S; Eigler A; Dauer M
    Gut; 2007 Sep; 56(9):1275-82. PubMed ID: 17395611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response.
    Takahara A; Koido S; Ito M; Nagasaki E; Sagawa Y; Iwamoto T; Komita H; Ochi T; Fujiwara H; Yasukawa M; Mineno J; Shiku H; Nishida S; Sugiyama H; Tajiri H; Homma S
    Cancer Immunol Immunother; 2011 Sep; 60(9):1289-97. PubMed ID: 21607557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.
    Ghansah T; Vohra N; Kinney K; Weber A; Kodumudi K; Springett G; Sarnaik AA; Pilon-Thomas S
    Cancer Immunol Immunother; 2013 Jun; 62(6):1083-91. PubMed ID: 23604104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.
    Miyashita T; Miki K; Kamigaki T; Makino I; Nakagawara H; Tajima H; Takamura H; Kitagawa H; Fushida S; Ahmed AK; Duncan MD; Harmon JW; Ohta T
    Clin Exp Med; 2017 Feb; 17(1):19-31. PubMed ID: 26449615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of Large Lymphoma Is Significantly Impeded with a Combination of Gemcitabine Chemotherapy and Dendritic Cells Intra-Tumor Vaccination.
    Zhu XJ; Yang ZF; Zhou JY; Liu L; Sun XM; Fan ZF; Hu SY; Chen YC; Li WX; Cao M; Wang LX
    PLoS One; 2015; 10(7):e0132799. PubMed ID: 26181041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of insulin on functional status of cord blood-derived dendritic cells and on dendritic cell-induced CTL cytotoxicity against pancreatic cancer cell lines.
    Liu QL; Wang YS; Wang JX
    Hepatobiliary Pancreat Dis Int; 2009 Oct; 8(5):529-34. PubMed ID: 19822498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
    Kimura Y; Tsukada J; Tomoda T; Takahashi H; Imai K; Shimamura K; Sunamura M; Yonemitsu Y; Shimodaira S; Koido S; Homma S; Okamoto M
    Pancreas; 2012 Mar; 41(2):195-205. PubMed ID: 21792083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine enhances cytotoxic activity of effector T-lymphocytes against chemo-resistant cholangiocarcinoma cells.
    Sawasdee N; Thepmalee C; Sujjitjoon J; Yongpitakwattana P; Junking M; Poungvarin N; Yenchitsomanus PT; Panya A
    Int Immunopharmacol; 2020 Jan; 78():106006. PubMed ID: 31780372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
    Koido S; Homma S; Okamoto M; Takakura K; Mori M; Yoshizaki S; Tsukinaga S; Odahara S; Koyama S; Imazu H; Uchiyama K; Kajihara M; Arakawa H; Misawa T; Toyama Y; Yanagisawa S; Ikegami M; Kan S; Hayashi K; Komita H; Kamata Y; Ito M; Ishidao T; Yusa S; Shimodaira S; Gong J; Sugiyama H; Ohkusa T; Tajiri H
    Clin Cancer Res; 2014 Aug; 20(16):4228-39. PubMed ID: 25056373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic cancer via the CARD9-BCL10-MALT1 / NF-κB pathway.
    Li Q; He J; Li S; Tian C; Yang J; Yuan H; Lu Y; Fagone P; Nicoletti F; Xiang M
    Clin Immunol; 2023 Mar; 248():109217. PubMed ID: 36581220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer
    Chen J; Guo XZ; Li HY; Zhao JJ; Xu WD
    World J Gastroenterol; 2017 Feb; 23(5):817-829. PubMed ID: 28223726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.